DUBLIN, Mar. 27, 2014 /PRNewswire/ --Research and Markets (http://www.researchandmarkets.com/research/pf27w4/therapeutic_class) has announced the addition of the "Therapeutic Class Overview: New Avatars of Microbes Super Bugs a Growing Threat Worldwide" report to their offering.
Novel approaches to treat infection is growing as the need is urgent! Misuse/overuse of antibiotics accelerated antimicrobial resistance (AMR) and has resulted in the emergence of super bugs which are posing life threatening challenges world wide. Many of the advances in medical treatment like cancer therapy; organ transplants etc. would go waste if the ability to fight infections during the treatment were not available. If that fails, the gains made in life-improving modern medical advantages will be lost creating a situation of - one step forward two step back. Novel approaches are immediately required to combat these super infections warranting need for new classes of antibiotics and other preventive/therapeutic approaches.
Discussed in this report:
- The evolution and global dissemination of AMR
- Unmet need in the critical setting esp. Gram Negative infections and CRE.
- Pipeline of novel targets being used to develop new drugs to treat infections and resistance.
- Pipeline of select drugs in mid and late clinical stage of development
- Alarming Facts about AMR
- Steps being taken by the regulatory authorities WW to address the issue and encourage novel therapeutics in this therapy area.
- Developing Countries- /ROW -- Trends in pathogens and resistance
- Role of diagnostics and preventive approach.
Key Topics Covered:
Introduction- Evolution and global dissemination of Anti Microbial Resistance (AMR)
Hitch Hiking and Globe Trotting by Bad Bugs-
Unmet need in the critical setting:
Need of the Hour- New Targets= New Antibiotic Class
Alarming Facts about AMR - CDC Alerts
Action by Regulatory Bodies -to Accelerate Drug development and Threat Awareness
Developing Countries- /ROW -- Trends in pathogens and resistance
Role of diagnostics and preventive approach
For more information visit http://www.researchandmarkets.com/research/pf27w4/therapeutic_class
Media Contact: Laura Wood , +353-1-481-1716, firstname.lastname@example.org
SOURCE Research and Markets